We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 350

Court declares Minister's decision restricting importation of drugs from two of Apotex's drug manufacturing facilities in India unlawful
  • Borden Ladner Gervais LLP
  • Canada
  • August 24 2016

Apotex et al. Brought a judicial review (JR) of the Minister of Health's August 2015 decision that varied the terms and conditions of Apotex's Drug


Claims under Section 8 of the NOC Regulations and under Ashby v. White struck in Ontario Court
  • Borden Ladner Gervais LLP
  • Canada
  • August 24 2016

In the Ontario Court, Apotex claimed damages pursuant to, inter alia , section 8 of the NOC Regulations. Pfizer brought a motion to strike out parts


Patent held Invalid for Ambiguity and Obviousness
  • Borden Ladner Gervais LLP
  • Canada
  • August 10 2016

Pollard challenged the validity of Scientific Games' (the successor to BABN) patent. Scientific Games counterclaimed with allegations of infringement


Bifurcation of Infringement and Validity Issues in Section 8 Action
  • Borden Ladner Gervais LLP
  • Canada
  • August 10 2016

This is a motion for bifurcation in an action brought pursuant to section 8 of the Patented Medicines (Notice of Compliance) Regulations


Ownership of Patent Question for Provincial Court before Patent Office Records Varied
  • Borden Ladner Gervais LLP
  • Canada
  • July 27 2016

In this case, SALT Canada Inc. (SALT) brought an application for a declaration pursuant to section 52 of the Patent Act to change the owner of the


Appeal of NOC Proceeding Dismissed as Moot, Despite Ongoing Section 8 Proceeding
  • Borden Ladner Gervais LLP
  • Canada
  • July 27 2016

Amgen was unsuccessful in a proceeding brought pursuant to the NOC Regulations. It appealed that decision. Apotex brought the within motion to


Dismissal of Motion to Vary Trial Decision in S. 8 case due to Later Infringement Finding Upheld on Appeal
  • Borden Ladner Gervais LLP
  • Canada
  • July 27 2016

AstraZeneca has appealed a decision on its motion seeking to vary a judgment in a decision on the merits of a section 8 case. Damages were awarded to


Solicitors for the defendants are not removed as counsel even though the plaintiffs had contacted them about representation years prior
  • Borden Ladner Gervais LLP
  • Canada
  • July 14 2016

The Federal Court has upheld a decision to not remove counsel as solicitors of record for the defendants. The plaintiffs had argued that when they


Prothonotary's Dismissal of a PM(NOC) application pursuant to s. 6(5)(b) upheld on appeal
  • Borden Ladner Gervais LLP
  • Canada
  • July 7 2016

Celltrion brought a motion pursuant to s. 6(5)(b) of the Patented Medicines (Notice of Compliance) Regulation (the NOC Regulations) to have the


Order of Prohibition Granted in respect of Compound Patent but Refused in respect of Patent Relating to Salt
  • Borden Ladner Gervais LLP
  • Canada
  • July 7 2016

This is an application under the Patented Medicines (Notice of Compliance) Regulations related to two patents. The first patent (the '840 Patent